1450620-52-6

Basic information

• Product Name: tert-butyl (3aR)-1,1-dioxotetrahydro-1H-1λ⁶-[1,2,3]oxathiazolo[3,4-a]pyrazine-5(3H)-carboxylate
• Synonyms: tert-butyl (3aR)-1,1-dioxotetrahydro-1H-1λ⁶-[1,2,3]oxathiazolo[3,4-a]pyrazine-5(3H)-carboxylate
• CAS NO: 1450620-52-6
• Molecular Weight: 278.329
• Mol File: 1450620-52-6.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl (3aR)-1,1-dioxotetrahydro-1H-1λ⁶-[1,2,3]oxathiazolo[3,4-a]pyrazine-5(3H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (3aR)-1,1-dioxotetrahydro-1H-1λ⁶-[1,2,3]oxathiazolo[3,4-a]pyrazine-5(3H)-carboxylate(1450620-52-6)
• EPA Substance Registry System: tert-butyl (3aR)-1,1-dioxotetrahydro-1H-1λ⁶-[1,2,3]oxathiazolo[3,4-a]pyrazine-5(3H)-carboxylate(1450620-52-6)

Safety Data

• Hazardous Substances Data: 1450620-52-6(Hazardous Substances Data)

Upstream product

• 278788-66-2 (R)-tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate 

Downstream Products

• 1450620-55-9 tert-butyl (3S)-3-((4-(tert-butoxycarbonyl)tetrahydro-2H-pyran-4-yl)methyl)-4-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)phenyl)-1-piperazinecarboxylate 
• 1450620-56-0 tert-butyl (3S)-3-((4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)methyl)-4-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)phenyl)-1-piperazinecarboxylate 
• 1450620-57-1 1,1,1,3,3,3-hexafluoro-2-(4-((2S)-2-((4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)methyl)-1-piperazinyl)phenyl)-2-propanol hydrochloride 
• 1450620-58-2 tert-butyl (5-(((3S)-3-((4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)methyl)-4-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)phenyl)-1-piperazinyl)sulfonyl)-2-pyridinyl)carbamate 
• 1450620-50-4 2-(4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-((4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)methyl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 1589082-06-3 (S)-3-cyanomethylpiperazine-1-carboxylic acid tert-butyl ester 
• 2158301-19-8 2-[(2S)-piperazin-2-yl]acetonitrile dihydrochloride 
• 1589081-71-9 (R)-3-(2-fluorophenoxymethyl)piperazine-1-carboxylic acid tert-butyl ester 
• 1589081-70-8 (R)-3-phenoxymethylpiperazine-1-carboxylic acid tert-butyl ester 
• 1589081-79-7 (R)-2-(2-fluorophenoxymethyl)piperazine 
• 660862-82-8 (R)-2-phenoxymethylpiperazine 

Relevant articles and documents

KRAS G12C INHIBITORS

The present invention provides compounds of the formula: where R1, R2, R3, R4, R5, A, B, and Y are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.

Kras-G12C inhibitor heterocyclic compounds

The invention relates to Kras-G12C inhibitor heterocyclic compounds represented by formula I, a preparation method thereof, and application of the Kras-G12C inhibitor heterocyclic compounds in prevention and treatment of tumor diseases such as lung cancer, colorectal cancer and pancreatic cancer. In the preparation process, the compounds of the general formula I are obtained through a series of reactions such as SN2 reaction, protection, coupling reaction, deprotection, condensation reaction and the like.

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12CInhibitor for the Treatment of Cancer

Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the target's resurgence. As previously reported, the tetrahydropyridopyrimidines were identified as irreversible covalent inhibitors of KRASG12C that bind in the switch-II pocket of KRAS and make a covalent bond to cysteine 12. Using structure-based drug design in conjunction with a focused in vitro absorption, distribution, metabolism and excretion screening approach, analogues were synthesized to increase the potency and reduce metabolic liabilities of this series. The discovery of the clinical development candidate MRTX849 as a potent, selective covalent inhibitor of KRASG12C is described.

FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS

The specification relates to compounds of Formula (A) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C

The present invention provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.

SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN

The present invention relates to sulfonyl compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.